Abstract: Provided are methods and articles of manufacture for use in stem cell therapy, for the treatment of diseases or conditions of SCA. Particularly, the invention provides a method for treating SCA, comprising parenterally or locally administering an effective amount of stem cells as a unit dosage to a subject, wherein the administration is performed with one or more treatment cycles, wherein one treatment cycle comprises dosing three unit dosages each at a dosing interval of two to six weeks.
Type:
Grant
Filed:
September 30, 2022
Date of Patent:
July 23, 2024
Assignee:
STEMINENT BIOTHERAPEUTICS INC.
Inventors:
Jennifer Hui-Chun Ho, Ryan Chang, Hsiu-Yu Lai, Wei-Kee Ong
Abstract: Provided are methods and articles of manufacture for use in stem cell therapy, for the treatment of diseases or conditions of SCA. Particularly, the invention provides a method for treating SCA, comprising parenterally or locally administering an effective amount of stem cells as a unit dosage to a subject, wherein the administration is performed with one or more treatment cycles, wherein one treatment cycle comprises dosing three unit dosages each at a dosing interval of two to six weeks.
Type:
Grant
Filed:
May 26, 2017
Date of Patent:
January 10, 2023
Assignee:
STEMINENT BIOTHERAPEUTICS INC.
Inventors:
Jennifer Hui-Chun Ho, Ryan Chang, Hsiu-Yu Lai, Wei-Kee Ong
Abstract: The invention unexpectedly found that an isolated and modified QPSC population has multi-potentiality, including: osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells). The QPSC population of the invention features a desirable immunomodulation ability, including inducing, enhancing, or suppressing an immune response and thus has potential value in the prevention and/or treatment of various immune diseases/disorders/conditions. The invention has effective homing ability and regulation ability in complement-dependent cytotoxicity, including the ability to block the activation of host complements and direct migration to the target area and the ability to enhance cell viability, and thus offers better cell protection and therapeutic efficacy in vivo in the prevention and/or treatment of various acute tissue injury, ischemic or degenerative diseases/disorders/conditions.
Type:
Application
Filed:
February 6, 2015
Publication date:
August 6, 2015
Applicant:
STEMINENT BIOTHERAPEUTICS INC.
Inventors:
Oscar Kuang-Sheng Lee, Jennifer Hui-Chun Ho, Wei-Kee Ong, Yu-Hsuan Chu
Abstract: The present invention relates to a cryopreservative device comprising an outer case, one or more layers of space for the cryo-bags, and two or more Teflon cryopreservative bags. The outer case has a cover lip for opening and closing. The Teflon cryopreservative bags are filled with a freezing resistant. In the present invention, the cryo-bags and the Teflon cryopreservative bags are crossly stacked in the cryopreservation device. The Teflon cryopreservative bags are designed to directly contact with the cryo-bags in order to obtain the effect of slow cell freezing.